Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (33)

I-41Marylore Chenel

Developing an In Vitro – In Vivo Correlation Model Using a Population Approach in NONMEM

Wednesday 10:15-11:45

I-47Jae Yong Chung

Modelling of Atorvastatin Pharmacokinetics in relation to SLCO1B1 genotype and Simulations for Bioequivalence Study

Wednesday 10:15-11:45

I-57Willem de Winter

Dynamics of a Two-Receptor Binding Model: How Affinities and Capacities Translate into Long- and Short-Term Behaviour and Physiological Corollaries

Wednesday 10:15-11:45

I-59Ivan Demin

Longitudinal model-based meta-analysis in rheumatoid arthritis: an application towards model based drug development

Wednesday 10:15-11:45

I-61Vincenzo Luca Di Iorio

Application of Stochastic Differential Equations to Disease Progression in a Neuropathic Pain Model in Rats

Wednesday 10:15-11:45

II-02

Pharmacokinetic bioequivalence analysis of biologics using nonlinear mixed effects modeling

Wednesday 14:55-16:10

II-03

Clinical trial simulations to design a crossover study assessing the equivalence on the pharmacodynamic surrogate marker between an immediate and a modified release formulations

Wednesday 14:55-16:10

II-10Charles Ernest

Multinomial Markov-chain model of sleep architecture in Phase-Advanced Subjects (PAS)

Wednesday 14:55-16:10

II-15Martin Fink

Diversity: Academia-Industry Collaborations on Modeling and Simulation to enhance Scientific Capability Development – The Novartis Experience

Wednesday 14:55-16:10

II-21Sathej Gopalakrishnan

Population PK/PD evaluation of the effect of dienogest on Hoogland Score in young healthy women

Wednesday 14:55-16:10

II-37Manish Gupta

Application of Two-Target Quasi-Steady-State (QSS) Model in Population Pharmacokinetic and Pharmacodynamic (PK-PD) Modeling of MNRP1685A in Cynomolgus Monkeys

Wednesday 14:55-16:10

II-38Serge Guzy

Optimizing The Entire Drug Development Process Using Pharmacometric Tools: From Preclinical To Marketing

Wednesday 14:55-16:10

II-50Candice Jamois

Title Pharmacokinetic-Pharmacodynamic Modeling of the Relationship between Aleglitazar Exposure and Lipids Response in Type 2 Diabetes Patients.

Wednesday 14:55-16:10

II-51Hyewon Jeon

A Population Pharmacokinetic/pharmacodynamic Approache of Drug X in Healthy Korean

Wednesday 14:55-16:10

II-59Thomas Kerbusch

Phase 2b dose selection for the treatment of autoimmune disorders leveraging comparator data

Wednesday 14:55-16:10

III-13

Development of a longitudinal model for characterizing adverse events of psychiatric drugs in routine clinical care

Thursday 09:50-11:05

III-22Hugh McDevitt

Technology Roadmap to Support Model Based Drug Development

Thursday 09:50-11:05

III-27Enrica Mezzalana

Title: Quantitative Assessment of First Night Effect in a Polysomnographic Insomnia Study through a Multinomial Mixed-Effect Markov-Chain Model

Thursday 09:50-11:05

III-31Flora Musuamba-Tshinanu

KPD modelling of trough FEV1 in chronic obstructive pulmonary disease (COPD).

Thursday 09:50-11:05

III-44Zinnia Parra-Guillen

Target Mediated Drug Disposition Model to Describe the Expression and Kinetics of IL12 And IFNγ in Gene Therapy

Thursday 09:50-11:05

III-52Olivier Petricoul

From Animal to Human with a new monoclonal antibody: An example of the use of pharmacokinetics only to assist on the choice of first in human dose.

Thursday 09:50-11:05

III-57Gregory Pinault

A structured approach to industrialize the data sourcing to support model based drug development

Thursday 09:50-11:05

III-65

Population PK/PD Modeling of a Hepatitis C NS3 Inhibitor

Thursday 09:50-11:05

IV-02Tarjinder Sahota

Parameterisation of biomarker response in the assessment of long term safety

Thursday 15:05-16:20

IV-07Yi SoJeong

Population Pharmacokinetics of a Novel Proton Pump Inhibitor, Drug Y, in Healthy Volunteers

Thursday 15:05-16:20

IV-13Andreas Steingoetter

A population pharmacokinetic model for Gd-DTPA in DCE-MRI

Thursday 15:05-16:20

IV-22David Ternant

Influence of the FcγRIIIa genetic polymorphism on the effect of antithymocyte globulins on lymphocyte populations in kidney transplantation

Thursday 15:05-16:20

IV-26

Evaluation of Circadian Rhythms in Hepatic CYP3A4 Activity Using Population Pharmacokinetics of Midazolam

Thursday 15:05-16:20

IV-32Pavan Vajjah

Effect of decontamination on the pharmacokinetics and pharmacodynamics of venlafaxine in overdose

Thursday 15:05-16:20

IV-49Pawel Wiczling

Pharmacokinetics and Pharmacodynamics of Propofol in ASA III Patients Undergoing Abdominal Aortic Surgery

Thursday 15:05-16:20

IV-52Dan Wright

Development of a Bayesian forecasting method for warfarin dose individualisation

Thursday 15:05-16:20

IV-53Rujia Xie

Model based meta-analysis (MBMA) to support the development of decision criteria in dental pain studies

Thursday 15:05-16:20

IV-55Shuying Yang

Predicting long term Placebo response based on short term observations:Meta-Analysis on FEV1 Response in Asthma Trials

Thursday 15:05-16:20